Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Go online to PeerView.com/GXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the use of newer cytotoxic strategies, targeted agents, epigenetic modifiers, and antibody-based treatment. Upon completion of this accredited CE activity, participants should be better able to: Describe factors for prognostic assessment and selection of treatment for patients with AML, including a diagnosis of CBF-AML; secondary AML; or AML with intermediate cytogenetics or TP53, FLT3, and/or IDH mutations, Summarize updated clinical evidence surrounding the use of novel cytotoxic, antibody, epigenetic, or targeted strategies, including novel combination strategies, for a range of AML patient populations and treatment settings, including upfront and post-remission therapy or in the management of relapsed/refractory AML, Design a personalized treatment plan for patients with newly diagnosed or relapsed/refractory AML who present with favorable, intermediate, or poor prognostic factors, Develop management protocols for unique adverse events associated with the use of novel therapeutics for AML.